Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.79 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.79 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.79 |
| ▸ | GCGR | P47871 | 10/20 | 0.79 |
| ▸ | RAF1 | P04049 | 3/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.77 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.65 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469323 | 1.00 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL8388860 | 0.99 | MAPK13 (0.77) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6464698 | 0.93 | NOX1 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL15075611 | 0.93 | MAPK13 (0.89) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6471005 | 0.89 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2649730 | 0.89 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469341 | 0.88 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2648503 | 0.87 | MAPK11 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6467858 | 0.87 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL8008805 | 0.86 | NOX1 (0.85) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | claimed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | claimed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | claimed |
| EP-0943616-B1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0623126-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| EP-0943616-A1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAPK13 2219/4885MAPK12 3250/4885MAPK11 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.